TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04807907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Directed Speech (IDS) Video + IDS Wall Calendar
Description: IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos).
Study: NCT05413382

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biofresh® 4plus
Description: Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
Study: NCT04707157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: given orally
Study: NCT06044480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of the same amount of saline solution instead of dexamethasone
Study: NCT05012956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Description: During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gynecologic laparoscopic surgery
Description: Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
Study: NCT01899833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-Sestamibi
Description: An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
Study: NCT05914909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD-214
Description: AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD-214
Description: AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05981833

Intervention type: DEVICE
Intervention: Repair with DAA (dermal allograft augmentation)
Description: Patients undergo rotator cuff repair with dermal allograft augmentation.
Study: NCT05021250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol marking
Description: HCC patients treated with TACE and the tumor marked with lipiodol.
Study: NCT05376176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1010904 ophthalmic suspension 0.03% BID
Description: 0.03% STN1010904 ophthalmic suspension BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1010904 ophthalmic suspension 0.1% BID
Description: 0.1% STN1010904 ophthalmic suspension BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) BID
Description: Placebo (vehicle) BID
Study: NCT04793542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lower-limb hot water immersion
Description: For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: lower-limb hot water immersion
Description: For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
Study: NCT05210530

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VCTX210A unit
Description: CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
Study: NCT05884203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caregiver socket
Description: A prosthetic socket whose shape was captured by a study helper using digital methods (i.e., 3D scanner). The digital file describing the socket dimensions will be sent to a central fabrication facility where the prosthetic socket will be manufactured.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetist socket
Description: A prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods. The hand cast will be plaster filled to create a positive model. A prosthetist socket will be fabricated over the positive model using thermoplastic materials.
Study: NCT05170906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex locomotion stimulus
Description: The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham stimulus
Description: The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg.
Study: NCT05114200

Intervention type: PROCEDURE
Intervention: Erector spinae plane block
Description: Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread.
Study: NCT05377047

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
Study: NCT05127837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTpro
Description: CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
Study: NCT04891315

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for soluble VAP-1 (sVAP-1).
Description: \~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
Study: NCT05473403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Description: Administration of high doses of corticosteroids as early as possible. Patient non-responder to treatment should lead to listing for emergency liver transplantation (LT).
Study: NCT05532774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI defocusing frame glasses
Description: AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
Study: NCT05259865

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic test for drug response prediction
Description: There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study.
Study: NCT04933175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparil
Description: Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
Study: NCT06154369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JoyPop
Description: Participants will be asked to use the app at least twice daily for the first 4 weeks with no further instructions on feature usage or time spent using the app.
Study: NCT06475859

Intervention type: OTHER
Intervention: Montreal Imaging Stress Test
Description: A mental stress test that induces stress via a series of arithmetic tasks participants need to solve in a few seconds.

Intervention type: OTHER
Intervention: Montreal Imaging Stress Test
Description: A mental stress test that induces stress via a series of arithmetic tasks participants need to solve in a few seconds.

Intervention type: OTHER
Intervention: Relaxation breathing
Description: 3 short sessions (4 minutes) of relaxation breathing

Intervention type: OTHER
Intervention: Relaxation breathing
Description: 3 short sessions (4 minutes) of relaxation breathing
Study: NCT05099952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of cheek cell and blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Meet with therapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in BBT-CI sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical records are reviewed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear actigraphy watch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05868109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide (iNO)
Description: In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
Study: NCT05272358

Intervention type: OTHER
Intervention: NETSARC network
Description: MDTB and/or surgery in NETSARC network

Intervention type: OTHER
Intervention: NETSARC network
Description: MDTB and/or surgery in NETSARC network

Intervention type: OTHER
Intervention: NETSARC network
Description: MDTB and/or surgery in NETSARC network
Study: NCT05320263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact aspiration Thrombectomy
Description: The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique.~A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stent retriever thrombectomy
Description: The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.
Study: NCT06120985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Countertop pitcher water filter
Description: Point-of-use drinking water filter
Study: NCT05609331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated Online Adaptive Planning
Description: The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic MRI-guided adaptive radiotherapy-SMART
Description: The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
Study: NCT05505955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965
Description: Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965
Description: Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965
Description: Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects took Placebo in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects took Placebo in Part 1 and Part 2.
Study: NCT05114421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04868526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Research participants will be assigned to two dietary conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Research participants will be assigned to two dietary conditions.
Study: NCT01419912

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cow's milk
Study: NCT06320769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plate Technique
Description: Using Plates, non-absorbable sutures or cerclage wires to guide the distal femoral physis towards rotational growth to correct deformity
Study: NCT06275360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)
Study: NCT04990089

Intervention type: DEVICE
Intervention: VIVO
Description: VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.
Study: NCT05009771

Intervention type: DRUG
Intervention: Intravenous patient-control analgesia
Description: At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.

Intervention type: DRUG
Intervention: Intravenous patient-control analgesia
Description: At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.

Intervention type: DRUG
Intervention: Dinalbuphine sebacate
Description: Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.

Intervention type: DRUG
Intervention: Dinalbuphine sebacate
Description: Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
Study: NCT04640467

Intervention type: DIAGNOSTIC_TEST
Intervention: Biophsical profile
Description: There are five components measured during the biophysical examination. A score of 2 points is given for each component that meets criteria. The test is continued until all criteria are met or 30 minutes have elapsed. The points are then added for a possible maximum score of 10. A total score of 10 out of 10 or 8 out of 10 with normal fluid is considered normal. A score of 6 is considered equivocal, and a score of 4 or less is abnormal.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebroplacental ratio
Description: CPR is the ratio of the Middle Cerebral Artery Pulsatility Index (MCA PI) to the Umbilical Artery Pulsatility Index (UA PI). The pulsatility indices will be measured from an automated trace of at least three consecutive waveforms of the relevant vessel in the absence of fetal breathing movements or uterine contractions. The angle of insonation will be as close to zero degrees as possible. The UA PI will be recorded from a free-floating section of cord, and the MCA PI will be obtained from the proximal third of the vessel (10, 14).
Study: NCT05444595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral plant-based dietary intervention
Description: Participants will meet with community health workers to receive information focused on healthy eating and consuming a traditional plant-based diet in a group format for the first few months followed by individual check-ins.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will meet with community health workers to receive general health information through individual check-ins.
Study: NCT05821764

Intervention type: OTHER
Intervention: Blood sample and data collection
Description: Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~* Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~* The cord blood sample (10 mL) immediately after delivery.~Data collection :~* A data collection sheet for the attention of the investigator (doctor or midwife) ;~* Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion).
Study: NCT06555549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEH113
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study: NCT04936295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Anlotinib
Description: Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
Study: NCT05595083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal dexmedetomidine group
Description: patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravouns dexmedetomidine group
Description: patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
Study: NCT05084911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyramax
Description: Pyronaridine-Artesunate(180/60mg) tablet for 3days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet for 3days.
Study: NCT06156956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation in capsules or suspension obtained from healthy unrelated donor introduced two times per treatment:~for capsules - FMT administration: day 7 (full dose) and days from 9 to 14 (prolonged intake regimen)~for suspension - FMT administration: day 7 and day 14